<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585867</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00140472</org_study_id>
    <nct_id>NCT04585867</nct_id>
  </id_info>
  <brief_title>Liposomal Bupivacaine vs Bupivacaine for Pain Control After Sternotomy</brief_title>
  <official_title>Liposomal Bupivacaine vs Bupivacaine for Pain Control After Sternotomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers hope to learn whether giving the longer-acting local anesthetic liposomal&#xD;
      bupivacaine prior to closing the sternum is more effective in managing pain following&#xD;
      sternotomy, than in patients who received standard bupivacaine before sternal closure.&#xD;
      Researchers will measure this based on how much IV pain medication is used, rates on&#xD;
      confusion, and time to remove the breathing tube.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">October 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>0 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>12 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>24 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>36 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>48 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>60 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid consumption in morphine equivalents</measure>
    <time_frame>72 hours post-surgery</time_frame>
    <description>Opioid consumption in morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to extubation in minutes will be retrieved via the electronic medical record</measure>
    <time_frame>30 days post operative</time_frame>
    <description>Time to extubation in minutes will be retrieved via the electronic medical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of sternal wound infection</measure>
    <time_frame>4-6 weeks postoperative visit</time_frame>
    <description>Presence of sternal wound infection will be retrieved via electronic medical record and at 30 day follow up for Society of Thoracic Surgery (STS) database data as well as sternal infection documented at standard postoperative visit at 4-6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative delirium as assessed by Confusion Assessment Method (CAM)-ICU</measure>
    <time_frame>30 days post operative</time_frame>
    <description>Postoperative delirium as assessed by CAM-ICU at hours 0,12,24,36,48,60,and 72 hours post-surgery will be retrieved via the electronic medical record</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pain Management</condition>
  <condition>Sternotomy</condition>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exparel (266mg) given by surgeon just prior to sternal closure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40ml of 0.125% bupivacaine given by surgeon just prior to sternal closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel</intervention_name>
    <description>The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>The injections will be performed under direct guidance by the cardiac surgeon at bilateral sternal-costal interspaces 1.5 cm lateral the sternal boarder at levels 2-6 in divided doses (2 ml/injection) just before the closure of the sternum near the end of the surgical procedure. The final 20 ml will be injected into the skin incision after closure</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over the age of 18 who present for elective open heart surgery that requires a&#xD;
             sternotomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urgent and emergency procedures,&#xD;
&#xD;
          -  preexisting sternal infections,&#xD;
&#xD;
          -  prior sternotomy,&#xD;
&#xD;
          -  preexisting pain syndromes,&#xD;
&#xD;
          -  current chronic home opioid use,&#xD;
&#xD;
          -  anterior rib or sternal masses,&#xD;
&#xD;
          -  allergy to any of the components of liposomal bupivacaine and plain bupivacaine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared Staab, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angie Ballew, DC, MS</last_name>
    <phone>9139457420</phone>
    <email>aballew@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Houchin</last_name>
      <email>ahouchin@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Jared Staab, DO</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

